C-myc and c-fos in human osteosarcoma:: Prognostic value of mRNA and protein expression

被引:147
作者
Gamberi, G
Benassi, MS
Bohling, T
Ragazzini, P
Molendini, L
Sollazzo, MR
Pompetti, F
Merli, M
Magagnoli, G
Balladelli, A
Picci, P
机构
[1] Rizzoli Orthoped Inst, Lab Oncol Res, I-40136 Bologna, Italy
[2] Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland
[3] Univ G DAnnunzio, Biol & Genet Inst, Chieti, Italy
关键词
osteosarcoma; oncogene; prognosis;
D O I
10.1159/000011912
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The c-myc and c-fos proto-oncogenes have several putative functions, including regulation of cell growth. In many neoplasms c-myc overexpression has been linked to poor prognosis. In order to study the role of c-myc and c-fos expression on the tumorigenesis, and the metastatic spread of osteosarcoma, frozen and paraffin-embedded tissue 38 primary osteosarcoma and 10 lung metastases were analyzed. The mRNA analysis was performed by quantitative reverse transcription-polymerase chain reaction and in situ hybridization. The protein expression was studied by Western blot analysis and immunohistochemistry. C-myc and c-fos were found overexpressed in a high percentage of the relapsed tumors and of the metastases, and overexpression of both oncogenes in the same tumor was strongly correlated to the development of metastases (p < 0.05), as 6 of the 7 primary turners overexpressing both the oncogenes gave metastases. In conclusion, both c-myc and c-fos are involved in the growth and spread of osteosarcoma and a synchronous overexpression of both oncogenes is highly significant for a metastatic potential of a primary tumor.
引用
收藏
页码:556 / 563
页数:8
相关论文
共 40 条
[1]  
[Anonymous], 1990, BONE SOFT TISSUE TUM
[2]  
BARRIOS C, 1994, ONCOLOGY, V51, P13
[3]   AMPLIFICATION OF C-MYC ONCOGENE AND ABSENCE OF C-HA-RAS POINT MUTATION IN HUMAN BONE SARCOMA [J].
BARRIOS, C ;
CASTRESANA, JS ;
RUIZ, J ;
KREICBERGS, A .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1993, 11 (04) :556-563
[4]   CLINICOPATHOLOGICAL CORRELATIONS AND SHORT-TERM PROGNOSIS IN MUSCULOSKELETAL SARCOMA WITH C-MYC ONCOGENE AMPLIFICATION [J].
BARRIOS, C ;
CASTRESANA, JS ;
KREICBERGS, A .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (03) :273-276
[5]  
BERNS EMJJ, 1992, CANCER RES, V52, P1107
[6]   Tumor size and prognosis in aggressively treated osteosarcoma [J].
Bieling, P ;
Rehan, N ;
Winkler, P ;
Helmke, K ;
Maas, R ;
Fuchs, N ;
Bielack, S ;
Heise, U ;
Jurgens, H ;
Treuner, J ;
Romanowski, R ;
Exner, U ;
Kotz, R ;
Winkler, K .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :848-858
[7]   MAX - A HELIX-LOOP-HELIX ZIPPER PROTEIN THAT FORMS A SEQUENCE-SPECIFIC DNA-BINDING COMPLEX WITH MYC [J].
BLACKWOOD, EM ;
EISENMAN, RN .
SCIENCE, 1991, 251 (4998) :1211-1217
[8]  
BORG A, 1991, ONCOGENE, V6, P137
[9]   AMPLIFICATION OF N-MYC IN UNTREATED HUMAN NEUROBLASTOMAS CORRELATES WITH ADVANCED DISEASE STAGE [J].
BRODEUR, GM ;
SEEGER, RC ;
SCHWAB, M ;
VARMUS, HE ;
BISHOP, JM .
SCIENCE, 1984, 224 (4653) :1121-1124
[10]   ONCOGENES, ANTIONCOGENES, AND THE REGULATION OF CELL-GROWTH [J].
CARBONE, M ;
LEVINE, AS .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1990, 1 (05) :248-253